Researchers at Winship Cancer Institute of Emory University assessed SARS-CoV-2 vaccine-induced binding and live virus response against the different variants in patients with Non-Small Cell Lung Carcinoma (NSCLC) and healthy adults after receiving both doses of the vaccine. Research details The study involved 82 NSCLC and 53 healthy adults who received both doses of the SARS-CoV-2 mRNA vaccine. COVID-19 specific binding and live virus neutralization response to wild type (WT) strain, delta, beta, and omicron variants were assessed using Meso Scale Discovery (MSD) and focus Reduction Neutralization Assay (FRNT).
Vaccine-induced antibody responses in NSCLC patients were compared with responses in healthy adults. Research findings Antibody binding titer was lower in NSCLC patients compared to healthy adults. They also had reduced live-virus neutralizing response to specific antibody…
